Resumo

OJEDA ARMAS, Iliana et al. New therapeutic approaches to dyslipidemias. ccm [online]. 2020, vol.24, n.2, pp. 702-722.  Epub 01-Jun-2020. ISSN 1560-4381.

Dyslipidemia is a major modifiable risk factor for cardiovascular disease due to atherosclerosis. A literature review was conducted with the descriptors dyslipidemia and treatment, in English and Spanish, in PubMed, PubMed Central, SciELO and Clinical Key. Emphasis was placed on new therapeutic modalities approved or under development that act mainly on molecular targets: subtilisin/kexin type 9 paraprotein converter (PCSK9), cholesterol ester transfer protein (CETP), angiopoietin-like protein 3 (ANGPTL3), receptor activated by peroxisome alpha proliferator (PPARα), acetyl-CoA carboxylase, ATP citrate lyase, diacylglycerol acyltransferase, apo A1, apo C-III, apo (a) and microsomal triglyceride transfer protein (MTP). The key therapeutic modalities were monoclonal antibodies (alirocumab and evolocumab), no-sense oligonucleotides (inclisiran, volanesorsen), vaccines, genome editing, enzyme inhibitors (gemcaben, prodigastat) and nutritional supplements (omega 3).

Palavras-chave : dyslipidemias; hypercholesterolemia; hypertriglyceridemia; low HDL-cholesterol; cardiovascular disease; prevention; lipid-lowering therapy.

        · resumo em Espanhol     · texto em Espanhol     · Espanhol ( pdf )